ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance

Request for Sample Pages

Published Date : 1 January 2012

Pages : 165

Add to Cart - ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance

ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance

Summary

Company, the leading business intelligence provider, has released its latest research, “ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance”, which provides in-depth analysis of the unmet needs, drivers and barriers that affect the global ENT disorders therapeutics market. The report analyzes the markets for ENT disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales value and annual cost of therapy are forecast until 2017 for key geographies in the five leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global markets.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Company’s team of industry experts.

Company’s analysis shows that the ENT disorders market will continue to grow marginally, largely due to the growing population and deteriorating environmental conditions. The prime reasons for the slow growth of the market are the generic domination and the weak product pipelines for all five key indications.

The global ENT disorders market was estimated to be worth $15.3 billion in 2010, having grown at a compound annual growth rate (CAGR) of 0.7% between 2002 and 2010. By 2017, the global ENT disorders market is forecast to reach $17.2 billion, indicating a CAGR of 1.6% between 2010 and 2017.

The ENT disorders M&A landscape has seen low levels of activity over the last decade, with only 16 deals signed from 2004-2011. The therapeutic area of focus for the M&A deals from 2004-2011 remained highly concentrated for sinusitis. Some deals had multiple ENT disorders as their therapeutic area of focus.

Scope

- Annualized market data for the ENT disorders market from 2002 to 2010, forecast forward to 2017.
- Analysis of the leading therapeutic segments, including tonsillitis, sinusitis, rhinitis, otitis media and tracheobronchitis.
- Analysis of the ENT disorders market in the leading geographies globally, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the ENT disorders market, including market size, annual cost of therapy and treatment usage patterns
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in the various phases of drug development
- Competitive benchmarking of leading companies. The key companies studied in this report are Abbott Laboratories, Bayer AG, Eli Lilly, GSK, J&J, Novartis AG, Merck & Co., Pfizer and Sanofi.
- Key M&A activities and licensing agreements that have taken place between 2004 and mid-2011 in the global ENT disorders market

Reasons to buy

- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms that can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Table of Contents :

1.1 List of Tables 7
1.2 List of Figures 9
2 ENT Disorders Market - Introduction 12
2.1 Company Report Guidance 12
3 ENT Disorders Market - Market Overview 13
3.1 Rising Global Population and Deteriorating Environmental Conditions Drive ENT Disorder Therapeutics 13
3.2 Gross Maldistribution 13
3.3 ENT Disorders Marked By Antibiotic Overuse 13
3.4 Entry of New Players Restricted by the Number of Generics and Stringent FDA Regulations 14
3.4.1 Ketolides - A New Class of Antibacterials 14
3.5 Revenue Forecasts 15
3.6 Annual Cost of Therapy 16
3.7 Treatment Usage Patterns 17
3.7.1 Diseased Population 19
3.7.2 Treatment Seeking Population 20
3.7.3 Diagnosed Population 21
3.7.4 Prescription Population 22
3.8 Drivers and Restraints of the ENT Disorders Market 23
3.8.1 ENT Disorders Market Drivers 23
3.8.2 ENT Disorders Market Restraints 24
4 ENT Disorders Market - Therapeutic Landscape 25
4.1 Tonsillitis Market 25
4.1.1 Introduction 25
4.1.2 Revenue Forecasts 26
4.1.3 Annual Cost of Therapy 28
4.1.4 Treatment Flow Algorithm 29
4.1.5 Treatment Usage Patterns 30
4.1.6 Profiles of Key Drugs in the Tonsillitis Market 36
4.1.7 Geographical Segmentation 38
4.2 Sinusitis Market 40
4.2.1 Introduction 40
4.2.2 Revenue Forecasts 41
4.2.3 Annual Cost of Therapy 44
4.2.4 Treatment Flow Algorithm 45
4.2.5 Treatment Usage Patterns 46
4.2.6 Profiles of Key Drugs in the Sinusitis Market 52
4.2.7 Geographical Segmentation 53
4.3 Rhinitis Market 55
4.3.1 Introduction 55
4.3.2 Revenue Forecasts 56
4.3.3 Annual Cost of Therapy 58
4.3.4 Treatment Flow Algorithm 59
4.3.5 Treatment Usage Patterns 60
4.3.6 Profiles of Key Drugs in the Rhinitis Market 66
4.3.7 Geographical Segmentation 67
4.4 Otitis Media Market 69
4.4.1 Introduction 69
4.4.2 Revenue Forecasts 70
4.4.3 Annual Cost of Therapy 72
4.4.4 Treatment Flow Algorithm 73
4.4.5 Treatment Usage Patterns 74
4.4.6 Profiles of Key Drugs in the Otitis Media Market 81
4.4.7 Geographical Segmentation 83
4.5 Tracheobronchitis Market 85
4.5.1 Introduction 85
4.5.2 Revenue Forecasts 86
4.5.3 Annual Cost of Therapy 88
4.5.4 Treatment Flow Algorithm 90
4.5.5 Treatment Usage Patterns 91
4.5.6 Profiles of Key Drugs in the Tracheobronchitis Market 96
4.5.7 Geographical Segmentation 99
5 ENT Disorders Market - Geographical Landscape 102
5.1 The US 105
5.1.1 Revenue Forecasts 105
5.1.2 Annual Cost of Therapy 106
5.1.3 Treatment Usage Patterns 107
5.2 Top Five Countries in Europe 113
5.2.1 Revenue Forecasts 113
5.2.2 Annual Cost of Therapy 114
5.2.3 Treatment Usage Patterns 115
5.3 Japan 121
5.3.1 Revenue Forecasts 121
5.3.2 Annual Cost of Therapy 122
5.3.3 Treatment Usage Patterns 123
6 ENT Disorders Market - Pipeline Analysis 128
6.1 Introduction 128
6.1.1 Research and Development Pipeline - Tonsillitis 130
6.1.2 Research and Development Pipeline - Sinusitis 131
6.1.3 Research and Development Pipeline - Rhinitis 134
6.1.4 Research and Development Pipeline - Otitis Media 138
7 ENT Disorders Market - Competitive Landscape 142
7.1 Competitive Profiling 142
7.1.1 Abbott Laboratories 142
7.1.2 Bayer AG 143
7.1.3 GlaxoSmithKline 144
7.1.4 Johnson & Johnson (J&J) 146
7.1.5 Merck & Co 147
7.1.6 Pfizer 148
7.1.7 Novartis AG 149
7.1.8 F. Hoffmann-La Roche Ltd. 150
7.1.9 Sanofi 151
8 ENT Disorders Market - Strategic Consolidations 153
8.1 Overview 153
8.2 ENT Disorders Market M&A Deals 153
8.2.1 M&A Deals by Geography 154
8.2.2 Deals by Type 155
8.2.3 Major M&A Deals 156
8.3 R&D Licensing Agreements 157
8.3.1 Deals by Indication 157
8.3.2 Deals by Geography 158
8.3.3 MerLion Pharmaceuticals Enters Into Licensing Agreement with Alcon Pharmaceuticals for Finafloxacin 158
9 ENT Disorders Market - Appendix 159
9.1 Market Definitions 159
9.2 Abbreviations 159
9.3 Research Methodology 160
9.3.1 Coverage 160
9.3.2 Secondary Research 160
9.3.3 Primary Research 161
9.3.4 Geographical Landscape 164
9.3.5 Pipeline Analysis 164
9.3.6 Competitive Landscape 164
9.3.7 Expert Panel Validation 164
9.4 Contact Us 164
9.5 Disclaimer 164
9.6 Sources 165

1.1 List of Tables

Table 1: ENT Disorders Market, Global, Revenue ($bn), 2002-2010 15
Table 2: ENT Disorders Market, Global, Revenue Forecasts ($bn), 2010-2017 15
Table 3: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2002-2010 16
Table 4: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2010-2017 16
Table 5: ENT Disorders Market, Global, Treatment Usage Patterns (million), 2002-2010 17
Table 6: ENT Disorders Market, Global, Treatment Usage Pattern (million), 2010-2017 18
Table 7: ENT Disorders Market, Global, Tonsillitis Revenue ($m), 2002-2010 26
Table 8: ENT Disorders Market, Global, Tonsillitis Revenue Forecasts ($m), 2010-2017 26
Table 9: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2002-2010 28
Table 10: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2010-2017 28
Table 11: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2002-2010 30
Table 12: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2010-2017 30
Table 13: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2002-2010 39
Table 14: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2010-2017 40
Table 15: ENT Disorders Market, Global, Sinusitis Revenue ($bn), 2002-2010 42
Table 16: ENT Disorders Market, Global, Sinusitis Revenue Forecasts ($bn), 2010-2017 42
Table 17: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2002-2010 44
Table 18: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2010-2017 44
Table 19: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2002-2010 46
Table 20: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2010-2017 47
Table 21: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($m), 2002-2010 54
Table 22: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($m), 2010-2017 55
Table 23: ENT Disorders Market, Global, Rhinitis Revenue ($bn), 2002-2010 56
Table 24: ENT Disorders Market, Global, Rhinitis Revenue Forecasts ($bn), 2010-2017 56
Table 25: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2002-2010 58
Table 26: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2010-2017 58
Table 27: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2002-2010 60
Table 28: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2010-2017 61
Table 29: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($m), 2002-2010 68
Table 30: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($m), 2010-2017 69
Table 31: ENT Disorders Market, Global, Otitis Media Revenue ($m), 2002-2010 70
Table 32: ENT Disorders Market, Global, Otitis Media Revenue Forecasts ($m), 2010-2017 70
Table 33: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2002-2010 72
Table 34: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2010-2017 72
Table 35: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2002-2010 74
Table 36: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2010-2017 75
Table 37: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2002-2010 84
Table 38: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2010-2017 85
Table 39: ENT Disorders Market, Global, Tracheobronchitis Revenue ($m), 2002-2010 86
Table 40: ENT Disorders Market, Global, Tracheobronchitis Revenue Forecasts ($m), 2010-2017 86
Table 41: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2002-2010 89
Table 42: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2010-2017 89
Table 43: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2002-2010 91
Table 44: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2010-2017 92
Table 45: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2002-2010 100
Table 46: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2010-2017 101
Table 47: ENT Disorders Market, Global, Revenue by Geography ($bn), 2002-2010 103
Table 48: ENT Disorders Market, Global, Revenue Forecasts by Geography ($bn), 2010-2017 104
Table 49: ENT Disorders Market, The US, Revenue ($bn), 2002-2010 105
Table 50: ENT Disorders Market, The US, Revenue Forecasts ($bn), 2010-2017 105
Table 51: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2002-2010 106
Table 52: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2010-2017 106
Table 53: ENT Disorders Market, The US, Treatment Usage Pattern (million), 2002-2010 107
Table 54: ENT Disorders Market, The US, Treatment Usage Patterns (million), 2010-2017 107
Table 55: ENT Disorders Market, Top Five Countries in Europe, Revenue ($bn), 2002-2010 113
Table 56: ENT Disorders Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2010-2017 113
Table 57: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010 114
Table 58: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017 114
Table 59: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002-2010 115
Table 60: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2010-2017 116
Table 61: ENT Disorders Market, Japan, Revenues ($m), 2002-2010 121
Table 62: ENT Disorders Market, Japan, Revenues ($m), 2010-2017 121
Table 63: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2002-2010 122
Table 64: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2010-2017 122
Table 65: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2002-2010 123
Table 66: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2010-2017 124
Table 67: ENT Disorders Market, Global, Tonsillitis Phase III Clinical Pipeline, 2011 130
Table 68: ENT Disorders Market, Global, Sinusitis Phase III Clinical Pipeline, 2011 131
Table 69: ENT Disorders Market, Global, Rhinitis Phase III Clinical Pipeline, 2011 135
Table 70: ENT Disorders Market, Global, Rhinitis Phase II Clinical Pipeline, 2011 136
Table 71: ENT Disorders Market, Global, Rhinitis Phase I Clinical Pipeline, 2011 137
Table 72: ENT Disorders Market, Global, Rhinitis Pre-clinical Pipeline, 2011 137
Table 73: ENT Disorders Market, Global, Otitis Media, Regulatory Filing and Phase III Clinical Pipeline, 2011 139

1.2 List of Figures

Figure 1: ENT Disorders Market, Global, Revenue Forecasts ($bn), 2002-2017 15
Figure 2: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2002-2017 16
Figure 3: ENT Disorders Market, Global, Treatment Usage Patterns (million), 2002-2017 17
Figure 4: ENT Disorders Market, Global, Diseased Population (million), 2002-2017 19
Figure 5: ENT Disorders Market, Global, Treatment Seeking Population (million), 2002-2017 20
Figure 6: ENT Disorders Market, Global, Diagnosis Population (million), 2002-2017 21
Figure 7: ENT Disorders Market, Global, Prescription Population (million), 2002-2017 22
Figure 8: ENT Disorders Market, Global, Drivers and Restraints, 2011 23
Figure 9: ENT Disorders Market, Global, Tonsillitis Revenue Forecasts ($m), 2002-2017 26
Figure 10: ENT Disorders Market, Global, Tonsillitis Therapeutics Market, Branded and Generic Share, (%), 2010 27
Figure 11: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2002-2017 28
Figure 12: ENT Disorders Market, Global, Tonsillitis, Treatment Flow Algorithm 29
Figure 13: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2002-2017 30
Figure 14: ENT Disorders Market, Global, Tonsillitis Diseased Population (million), 2002-2017 32
Figure 15: ENT Disorders Market, Global, Tonsillitis Treatment Seeking Population (million), 2002-2017 33
Figure 16: ENT Disorders Market, Global, Tonsillitis Diagnosis Population (million), 2002-2017 34
Figure 17: ENT Disorders Market, Global, Tonsillitis Prescription Population (million), 2002-2017 35
Figure 18: ENT Disorders Market, Global, Tonsillitis Market Segmentation by Geography, (%), 2010 and 2017 38
Figure 19: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2002-2017 39
Figure 20: ENT Disorders Market, Global, Sinusitis Revenue Forecasts ($bn), 2002-2017 41
Figure 21: ENT Disorders Market, Global, Sinusitis Therapeutics Market, Branded and Generic Share, (%), 2010 and 2017 43
Figure 22: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2002-2017 44
Figure 23: ENT Disorders Market, Global, Sinusitis, Treatment Flow Algorithm 45
Figure 24: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2002-2017 46
Figure 25: ENT Disorders Market, Global, Sinusitis Diseased Population (million), 2002-2017 48
Figure 26: ENT Disorders Market, Global, Sinusitis Treatment Seeking Population (million), 2002-2017 49
Figure 27: ENT Disorders Market, Global, Sinusitis Diagnosed Population (million), 2002-2017 50
Figure 28: ENT Disorders Market, Global, Sinusitis Prescription Population (million), 2002-2017 51
Figure 29: ENT Disorders Market, Global, Sinusitis Market Segmentation by Geography, 2010 and 2017 53
Figure 30: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($bn), 2002-2017 54
Figure 31: ENT Disorders Market, Global, Rhinitis Revenue Forecasts ($bn), 2002-2017 56
Figure 32: ENT Disorders Market, Global Rhinitis, Branded and Generic Share, (%), 2010 and 2017 57
Figure 33: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2002-2017 58
Figure 34: ENT Disorders Market, Global, Rhinitis, Treatment Flow Algorithm 59
Figure 35: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2002-2017 60
Figure 36: ENT Disorders Market, Global, Rhinitis Diseased Population (million), 2002-2017 62
Figure 37: ENT Disorders Market, Global, Rhinitis Treatment Seeking Population (million), 2002-2017 63
Figure 38: ENT Disorders Market, Global, Rhinitis Diagnosis Population (million), 2002-2017 64
Figure 39: ENT Disorders Market, Global, Rhinitis Prescription Population (million), 2002-2017 65
Figure 40: ENT Disorders Market, Global, Rhinitis Market Segmentation by Geography, 2010 and 2017 67
Figure 41: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($bn), 2002-2017 68
Figure 42: ENT Disorders Market, Global, Otitis Media Revenue Forecasts ($m), 2002-2017 70
Figure 43: ENT Disorders Market, Global, Otitis Media Therapeutics Market, Branded and Generic Share, (%), 2010 and 2017 71
Figure 44: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2002-2017 72
Figure 45: ENT Disorders Market, Global, Otitis Media, Treatment Flow Algorithm 73
Figure 46: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2002-2017 74
Figure 47: ENT Disorders Market, Global, Otitis Media, Causes (%), 2011 76
Figure 48: ENT Disorders Market, Global, Otitis Media Diseased Population (million), 2002-2017 77
Figure 49: ENT Disorders Market, Global, Otitis Media Treatment Seeking Population (million), 2002-2017 78
Figure 50: ENT Disorders Market, Global, Otitis Media Diagnosed Population (million), 2002-2017 79
Figure 51: ENT Disorders Market, Global, Otitis Media Prescription Population (million), 2002-2017 80
Figure 52: ENT Disorders Market, Global, Otitis Media Market Segmentation by Geography, (%), 2010 and 2017 83
Figure 53: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2002-2017 84
Figure 54: ENT Disorders Market, Global, Tracheobronchitis Revenue Forecasts ($m), 2002-2017 86
Figure 55: ENT Disorders Market , Global, Tracheobronchitis Therapeutics Market, Branded and Generic Share (%), 2010 and 2017 87
Figure 56: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2002-2017 88
Figure 57: ENT Disorders Market, Global, Tracheobronchitis, Treatment Flow Algorithm 90
Figure 58: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2002-2017 91
Figure 59: ENT Disorders Market, Global, Tracheobronchitis Diseased Population (million), 2002-2017 92
Figure 60:ENT Disorders Market, Global, Tracheobronchitis Treatment Seeking Population (million), 2002-2017 93
Figure 61: ENT Disorders Market, Global, Tracheobronchitis Diagnosed Population (million), 2002-2017 94
Figure 62: ENT Disorders Market, Global, Tracheobronchitis Prescription Population (million), 2002-2017 95
Figure 63: ENT Disorders Market, Global, Tracheobronchitis Market Segmentation by Geography, 2010 and 2017 99
Figure 64: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2002-2017 100
Figure 65: ENT Disorders Market, Global, Market Share by Geography, (%), 2010 and 2017 102
Figure 66: ENT Disorders Market, Global, Revenue Forecasts by Geography ($bn), 2002-2017 103
Figure 67: ENT Disorders Market, The US, Revenue Forecasts ($bn), 2002-2017 105
Figure 68: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2002-2017 106
Figure 69: ENT Disorders Market, The US, Treatment Usage Pattern (million), 2002-2017 107
Figure 70: ENT Disorders Market, The US, Diseased Population (million), 2002-2017 109
Figure 71: ENT Disorders Market, The US, Treatment Seeking Population (million), 2002-2017 110
Figure 72: ENT Disorders Market, The US, Diagnosed Population (million), 2002-2017 111
Figure 73: ENT Disorders Market, The US, Prescription Population (million), 2002-2017 112
Figure 74: ENT Disorders Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2002-2017 113
Figure 75: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017 114
Figure 76: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002-2017 115
Figure 77: ENT Disorders Market, Top Five Countries in Europe, Diseased Population (million), 2002-2017 117
Figure 78: ENT Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2002-2017 118
Figure 79: ENT Disorders Market, Top Five Countries in Europe, Diagnosed Population (million), 2002-2017 119
Figure 80: ENT Disorders Market, Top Five Countries in Europe, Prescription Population (million), 2002-2017 120
Figure 81: ENT Disorders Market, Japan, Revenues ($m), 2002-2017 121
Figure 82: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2002-2017 122
Figure 83: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2002-2017 123
Figure 84: ENT Disorders Market, Japan, Diseased Population (million), 2002-2017 124
Figure 85: ENT Disorders Market, Japan, Treatment Seeking Population (million), 2002-2017 125
Figure 86: ENT Disorders Market, Japan, Diagnosis Population (million), 2002-2017 126
Figure 87: ENT Disorders Market, Japan, Prescription Population (million), 2002-2017 127
Figure 88: ENT Disorders Market, Global, R&D Pipeline by Indication (%), 2011 128
Figure 89: ENT Disorders Market, Global, R&D Pipeline by Phase (%), 2011 129
Figure 90: ENT Disorders Market, Global, R&D Pipeline by Phase in Sinusitis Market (%), 2011 131
Figure 91: ENT Disorders Market, Global, R&D Pipeline by Phase in Rhinitis Market (%), 2011 134
Figure 92: ENT Disorders Market, Global, R&D Pipeline by Phase in Otitis Media (%), 2011 138
Figure 93: ENT Disorders Market, Global, SWOT - Abbott Laboratories, 2011 142
Figure 94: ENT Disorders Market, Global, SWOT - Bayer AG, 2011 143
Figure 95: ENT Disorders Market, Global, SWOT - GSK, 2011 145
Figure 96: ENT Disorders Market, Global, SWOT - Johnson & Johnson, 2011 146
Figure 97: ENT Disorders Market, Global, SWOT - Merck, 2011 147
Figure 98: ENT Disorders Market, Global, SWOT - Pfizer, 2011 148
Figure 99: ENT Disorders Market, Global, SWOT - Novartis, 2011 149
Figure 100: ENT Disorders Market, Global, SWOT - Roche, 2011 151
Figure 101: ENT Disorders Market, Global, SWOT- Sanofi, 2011 152
Figure 102: ENT Disorders Market, Global, M&A Deals by Indication (%), 2004-2011 153
Figure 103: ENT Disorders Market, Global, Major M&A Deals By Geography (%), 2004-2011 154
Figure 104: ENT Disorders Market, Global, Major M&A Deals By Type (%), 2004-2011 155
Figure 105: ENT Disorders Market, Global, Licensing Deals by Indication (%), 2004-2011 157
Figure 106: ENT Disorders Market, Global, Licensing Deals By Geography, (%), 2004-2011 158
Figure 107: Company Market Forecasting Model 163

Companies Mentioned

Abbott Laboratories
Bayer AG
GlaxoSmithKline
Johnson & Johnson (J&J)
Merck & Co
Pfizer
Novartis AG
F. Hoffmann-La Roche Ltd.
Sanofi

Published By : GBI Research

PDF Format Reports will be
delivered by email within
12 to 24 hours after placing
the order (Mon-Fri IST)

Australia Research Reports
Brazil Research Reports
Asia Research Reports
China Research Reports
Canada Research Reports
Europe Research Reports
France Research Reports
Egypt Research Reports
Global Research Reports
Greece Research Reports
Germany Research Reports
Japan Research Reports
India Research Reports
Ireland Research Reports
Korea Research Reports
Mexico Research Reports
Maldives Research Reports
New Zealand Research Reports
Netherland Research Reports
Poland Research Reports
Russia Research Reports
South Africa Research Reports
Sri Lanka Research Reports
Singapore Research Reports
Switzerland Research Reports
UK Research Reports
USA Research Reports
UAE Research Reports
Uruguay Research Reports

ExxonMobil Company Analysis
Toyota Motors Company Analysis
ConocoPhillips Company Analysis
Sinopec Company Analysis
Total S.A. Company Analysis
Verizon Company Analysis
Gazprom Company Analysis
JPMorgan Company Analysis
Chevron Company Analysis
E.ON Company Analysis
PetroChina Company Analysis
Allianz Company Analysis
AXA Company Analysis
Carrefour Company Analysis
General Electric Company Analysis
Bank of America Company
Assicurazioni Generali Company
Samsung Electronics Company
GDF Suez Company Analysis
McKesson Corporation Company
Volkswagen Group Company
Royal Dutch Shell Company